Bayer in Gene Therapy Collaboration With Mammoth Biosciences

Bayer in Gene Therapy Collaboration With Mammoth Biosciences
A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany, on Aug. 9, 2019. Wolfgang Rattay/Reuters
Reuters
Updated:

FRANKFURT—Bayer on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts.

Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements.